News
Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., July 30, 2024 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining cutting-edge computational and experimental technologies, will report second-quarter 2024 financial results and corporate highlights after the close of U.S. financial markets on Tuesday, August 6, 2024.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining cutting-edge experimental and computational technologies to bring transformative therapies to patients. As the first of a new generation of biotechs built at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what is possible in drug discovery. Its Dynamo™ platform integrates a series of cutting-edge experimental and computational approaches designed for protein drug targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is to advance small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, visit www.relaytx.com or Follow us on Twitter.
Contact:
Megan Goulart
617-545-5526
mgoulart@relaytx.com
Media:
And Budwick
1AB
973-271-6085
dan@1abmedia.com